EMA committee recommends orphan drug status for acalabrutinib for three indications
Last December, AstraZeneca agreed to acquire a 55% stake in privately-owned biotech firm Acerta Pharma for $4bn. Acalabrutinib has been recommended as an orphan product for chronic lymphocytic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.